Výsledky vyhledávání - "Brad, Wasserman"

Akademický článek

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance

Autor: Vasiliki Pelekanou, Daniel E. Carvajal-Hausdorf, Mehmet Altan, Brad Wasserman, Cristobal Carvajal-Hausdorf, Hallie Wimberly, Jason Brown, Donald Lannin, Lajos Pusztai, David L. Rimm

Publikováno v: Breast Cancer Research, Vol 19, Iss 1, Pp 1-11 (2017)

Abstract Background The effects of neoadjuvant chemotherapy on immune markers remain largely unknown. The specific aim of this study was to assess stromal tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) protein expression

Externí odkaz: https://doaj.org/article/c250518058be4c34b284ca5bdaf2582c

Zobrazit plný text záznamu

High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence

Autor: N Wu, David L. Rimm, Veronique Neumeister, Brad Wasserman, Wendy Wong, Edwin W. Lai, VC Chu, Kenneth E. Ho, Jodi Weidler, Daniel E. Carvajal-Hausdorf, Michael Bates

Publikováno v: Laboratory investigation; a journal of technical methods and pathology

Background Historically, mRNA measurements have been tested on several commercially available platforms, but none have gained broad acceptance for assessment of HER2. An mRNA measurement, as a continuous value, has the potential for use in adjudicati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d384a288cb48d718e5efd8d582d735d
https://doi.org/10.1038/labinvest.2017.93

Zobrazit plný text záznamu

Cleaning and Sterilization of Used Cardiac Implantable Electronic Devices With Process Validation

Publikováno v: JACC: Clinical Electrophysiology. 3:623-631

Objectives This study sought to develop a validated, reproducible sterilization protocol, which could be used in the reprocessing of cardiac implantable electronic devices (CIEDs). Background Access to cardiac CIED therapy in high-income and in low-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d968f9fc0208b4f4a0c7150176c56ab
https://doi.org/10.1016/j.jacep.2016.12.007

Zobrazit plný text záznamu

Using reconditioned pacemakers to treat bradycardia in Africa

Autor: Aimé Bonny, Brad Wasserman, George Samson, Zaheer Yousef, Kim A. Eagle, James B.W. Russell, Olujimi A. Ajijola, Kevin Wunderly, Constantine Akwanalo, Craig Allmendinger, Bongani M. Mayosi, George Nel, Kevin J. Weatherwax, Sheldon Davis, Thomas Crawford, Mahmoud U Sani, Ashely Chin, Balasundaram Lavan

Publikováno v: Nature reviews. Cardiology. 15(12)

Pacemaker therapy is inaccessible to most patients with bradycardia in Africa. Use of reconditioned pacemakers has been proposed as a safe, efficacious, and ethical means of delivering this therapy. A collaboration between PASCAR, Pace4Life, and Proj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e98be68ab23d98c71f2a88cc8de1e0b
https://pubmed.ncbi.nlm.nih.gov/30209354

Zobrazit plný text záznamu

Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations

Autor: Mehmet Altan, David L. Rimm, James W. Smithy, Kurt A. Schalper, Nikita Mani, Brad Wasserman, Yuting Liu, Maria I. Toki, Rasikh Tuktamyshov, Konstantinos N. Syrigos

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 13(12)

PURPOSE: PD-1/PD-L1 axis inhibitors have been proven effective, especially in patients with tumors expressing Programmed Death Ligand 1 (PD-L1). Their clinical efficacy in patients with epidermal growth factor receptor (EGFR) activating mutations is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99baab9ca4a431490b24e2035777db7f
https://pubmed.ncbi.nlm.nih.gov/30267840

Zobrazit plný text záznamu

Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial

Autor: Brad Wasserman, David L. Rimm, Debasish Tripathy, Zeina Nahleh, Daniel F. Hayes, Peggy L. Porter, Ying-Chun Lo, Vasiliki Pelekanou, William E. Barlow, Julie Gralow, Marie Kristin von Wahlde, Lajos Pusztai, Gabriel N. Hortobagyi, Borbála Székely, Christos Hatzis

Publikováno v: Molecular cancer therapeutics. 17(6)

Our aim was to examine the association of pretreatment tumor-infiltrating lymphocyte (TIL) count and PD-L1 levels with pathologic complete response (pCR) and assess immune marker changes following treatment in tumor specimens from the S0800 clinical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbf93ec41df225c0825a7c78b1cde553
https://pubmed.ncbi.nlm.nih.gov/29588392

Zobrazit plný text záznamu

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance

Autor: Cristobal Carvajal-Hausdorf, Brad Wasserman, Lajos Pusztai, David L. Rimm, Hallie Wimberly, Vasiliki Pelekanou, Mehmet Altan, Daniel E. Carvajal-Hausdorf, Donald R. Lannin, Jason R. Brown

Publikováno v: Breast Cancer Research : BCR
Breast Cancer Research, Vol 19, Iss 1, Pp 1-11 (2017)

Background The effects of neoadjuvant chemotherapy on immune markers remain largely unknown. The specific aim of this study was to assess stromal tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) protein expression in a coho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb1cc4dad808bde3bc5f074f7b247f70
http://europepmc.org/articles/PMC5547502

Zobrazit plný text záznamu

Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer

Autor: Daniel E. Carvajal-Hausdorf, Brad Wasserman, Vasiliki Pelekanou, Gang Han, David L. Rimm, Nikita Mani, Jamaal Rehman, Kurt A. Schalper, Joseph McLaughlin

Publikováno v: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

PD-L1 is expressed in a percentage of lung cancer patients and those patients show increased likelihood of response to PD-1 axis therapies. However, the methods and assays for the assessment of PD-L1 using immunohistochemistry are variable and PD-L1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e02498727fe6a20df76699c4d4fa141f
https://pubmed.ncbi.nlm.nih.gov/27834350

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání